MapLight Therapeutics, Inc. Common Stock Net Assets
MapLight Therapeutics, Inc. Common Stock net assets. Based on the latest financial reports, MapLight Therapeutics, Inc. Common Stock (MPLT) has net assets worth $348.30 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($368.35 Million) and total liabilities ($20.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore MapLight Therapeutics, Inc. Common Stock (MPLT) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $348.30 Million |
| % of Total Assets | 94.56% |
| Annual Growth Rate | 179.98% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 100.77 |
Net Assets of MapLight Therapeutics, Inc. Common Stock (2022–2025)
Net assets of MapLight Therapeutics, Inc. Common Stock from 2022 to 2025. This chart illustrates how MapLight Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See MapLight Therapeutics, Inc. Common Stock (MPLT) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for MapLight Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual net assets of MapLight Therapeutics, Inc. Common Stock from 2022 to 2025. For live market cap and overall valuation, see market cap of MapLight Therapeutics, Inc. Common Stock.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $458.37 Million | +297.91% |
| 2024-12-31 | $115.19 Million | +61.60% |
| 2023-12-31 | $71.28 Million | +241.55% |
| 2022-12-31 | $20.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MapLight Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 29444100100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
MapLight Therapeutics, Inc. Common Stock Net Assets Breakdown (December 2025)
MapLight Therapeutics, Inc. Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Comprehensive Income | $-228.00K | -0.05% |
| Other Components | $819.12 Million | 178.70% |
| Total Equity | $458.37 Million | 100.00% |
MapLight Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of MapLight Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Qingdao Richmat Intelligence Technology Co. Ltd. A
SHE:301320
|
$297.50 Million |
|
Chengdu Shengbang Seals Co.Ltd.
SHE:301233
|
$297.51 Million |
|
Arad Ltd
TA:ARD
|
$297.56 Million |
|
Taewoong Co.Ltd
KQ:044490
|
$297.61 Million |
|
Malaysian Resources Corporation
KLSE:1651
|
$297.24 Million |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
$297.21 Million |
|
Perpetual Equity Investment Company Ltd
AU:PIC
|
$297.13 Million |
|
Nanjing OLO Home Furnishing
SHG:603326
|
$297.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MapLight Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 115,195,000 to 458,372,000, a change of 343,177,000 (297.9%).
- Net loss of 161,152,000 reduced equity.
- New share issuances of 474,556,000 increased equity.
- Other comprehensive income decreased equity by 391,000.
- Other factors increased equity by 30,164,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-161.15 Million | -35.16% |
| Share Issuances | $474.56 Million | +103.53% |
| Other Comprehensive Income | $-391.00K | -0.09% |
| Other Changes | $30.16 Million | +6.58% |
| Total Change | $- | 297.91% |
Book Value vs Market Value Analysis
This analysis compares MapLight Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.65x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 13.52x to 0.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $0.50 | $6.81 | x |
| 2023-12-31 | $1.72 | $6.81 | x |
| 2024-12-31 | $2.78 | $6.81 | x |
| 2025-12-31 | $10.41 | $6.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MapLight Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-35.16%) is above the historical average (-81.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -143.82% | 0.00% | 0.00x | 1.89x | $-32.10 Million |
| 2023 | -78.15% | 0.00% | 0.00x | 1.28x | $-62.84 Million |
| 2024 | -67.35% | 0.00% | 0.00x | 1.19x | $-89.10 Million |
| 2025 | -35.16% | 0.00% | 0.00x | 1.05x | $-206.99 Million |
Industry Comparison
This section compares MapLight Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MapLight Therapeutics, Inc. Common Stock (MPLT) | $348.30 Million | -143.82% | 0.06x | $297.26 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irrit… Read more